Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. - Wikidata - awgldk - TriplyDB

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

http://www.wikidata.org/entity/Q46452033

about

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.Current approaches to the management of new-onset ulcerative colitis.Mesalazine in inflammatory bowel disease: a trendy topic once again?Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.Current and emerging drugs for the treatment of inflammatory bowel disease.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine.Second Korean guidelines for the management of ulcerative colitis.Efficacy and safety of drugs for ulcerative colitis.MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.Optimization of conventional therapy in patients with IBD.Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.Indian Society of Gastroenterology consensus on ulcerative colitis.Mesalazine for the treatment of inflammatory bowel disease.The role of mucosal healing in the treatment of patients with inflammatory bowel disease Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity.Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease 5-ASA in ulcerative colitis: improving treatment compliance.Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.Targeting mucosal healing in Crohn's disease.Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update.Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.Effect of oral hepatocyte growth factor gene mediated by attenuated salmonella on 2-, 4-, 6-trinitro-benzene-sulfonic-acid-induced ulcerative colitis in rat.MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.

P2860

Q24185876-025897CE-309A-4544-B7A1-DFF7047C79AB Q24198024-87060B31-DE99-4F01-92BA-06697D07BCAB Q33406895-2EFED3D2-B887-459A-812E-5B1E8E4142E1 Q33633288-17EE5AD4-43C6-4505-9DB4-818E7F16B243 Q33779797-03AB7D45-E34F-44FE-BC1F-281CEFA957EC Q33819512-B2F9FD71-B0F5-4D12-8315-EEA9E5E9516C Q33950898-D4DC4CEF-180D-4B22-B9FD-14912B97C892 Q34883210-84027B3C-FD05-4B87-9519-E2E7E3922BDB Q36144377-9BD11E08-2061-4070-8B38-0A4C3C2A85A8 Q36172156-262C555F-10A2-4FB6-911E-D5CB1CBCDC04 Q37129225-CCE9BA6B-FF84-40F3-B291-5570862EAAC4 Q37423752-5575C3FF-85A9-4236-911C-68F4E826CAB9 Q37662503-FE5B7078-86EE-47CA-87BF-9D1700056433 Q37727232-03162DE6-DD8E-4286-AD71-2435172D0909 Q37833064-DFF4596E-F2E2-4842-B780-351FFE0D089D Q37942292-E0465BC0-AB81-420D-9182-58171243941D Q38042702-E840CB25-75AD-4098-A66C-EC062C2155AB Q38055371-B273AD9C-1FD7-4D64-99A5-1BA83E8A3E50 Q38114476-1494E097-972B-4909-BF76-D1A4F3D1DAEA Q38176299-BD38C11B-A7BC-4F2A-B2F1-BE4F19C74107 Q39098635-F0AB3ACB-2418-46D6-A1CC-4D659C5598A2 Q39247690-DA891C5D-6A89-4F8A-85AA-EEDA72B9E854 Q41582729-E0E2501A-602F-42BE-99E1-B0C931052F0B Q41821193-C2FA83ED-E8B0-4145-8931-5944284C47A3 Q41891210-701C66C8-7B49-4358-9121-8757AD3E648C Q42560059-F0A66CA6-0417-4B9F-A156-9FE90992B9A5 Q42651189-5F9CD11D-27EB-4B60-89FB-7ED4C5981E26 Q42857508-BE22BE49-704E-4BC6-8EA0-4AEDAB260731 Q43144390-C4537BB6-009B-457E-AD57-C99484A86D51 Q45861878-057C97C9-C654-40B6-93F4-34F222E8807C Q47958039-5610CCB1-E30F-4CD3-B382-E1BBECBC4D6D Q48064807-D1257B90-FA10-4D8D-A270-9D36AD86537B Q50037484-D155C5CC-D51E-4EEB-8859-C249D8E41C67 Q55439079-06594E46-C99A-404E-8E7A-26871F1E32E5

P2860

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

http://www.wikidata.org/entity/Q46452033

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@en

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@nl

type

label

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@en

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@nl

prefLabel

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@en

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@nl

P1433

Q46452033-C61A1E65-7727-4566-AEBD-B18A54388BD1

P1476

Q46452033-023F4B6B-127F-4B6C-8DA1-BA07104FF038

P2093

Q46452033-03D6C7D5-8093-42E9-947D-22BEEA42AC89

Q46452033-80D06E5E-57B0-4E17-80C2-4120986EDD2A

Q46452033-860DC34C-548F-4612-BB3D-E89DE1DC9CBE

Q46452033-B5AB63B0-A7BE-401A-B20E-29629A63F9E4

Q46452033-CF6A79CC-D242-476F-BCB1-EE3C493DD10A

Q46452033-FBE9B626-5C21-446B-B3CB-6A2535980608

P2860

Q46452033-005C694E-63A6-455F-A9FF-40BCC173EC7A

Q46452033-02192B87-158A-4DDE-A9F1-BEDB369D31CD

Q46452033-236C6CE0-FDDA-434B-B0D7-6B7A7ABD99D5

Q46452033-67DF4EA3-855C-46B4-9A23-448198A6C550

Q46452033-6CD25B91-156B-46CE-827F-FA03C0173A38

Q46452033-76CBBC5D-B101-4A9E-B860-7C793194B821

Q46452033-8A03CA84-7F10-4B27-BD29-7C8409E43F76

Q46452033-A18A2590-5954-43FC-843D-E712D2AB16CE

Q46452033-A53D6397-DD18-4851-8D20-8A5E5F9243DF

Q46452033-A9BAC9CC-ADA6-4445-A0F0-355439492E22

P304

Q46452033-87C8EA87-A352-40DD-B321-F57F42FD5E1B

P31

Q46452033-6D10ADF9-A207-4065-8461-CB2B32C10171

P356

Q46452033-C5D5D350-3F23-4FAC-9570-35A38A26D73D

P433

Q46452033-796D4936-9EF5-439E-9EF1-3F7397DA48F0

P478

Q46452033-48DA221A-A7FC-497F-9BCF-271BE2672F41

P50

Q46452033-732B7C59-6243-474A-A19A-B93384E5FF20

P577

Q46452033-58B0D1C5-4405-4DBB-89F5-6DAC3C7340C2

P5875

Q46452033-CD08543D-9196-4E81-BC90-792D05D9B586

P698

Q46452033-2A0AD558-6552-45EE-AD6D-8C8672392E69

P356

P1433

Inflammatory Bowel Diseases

P1476

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@en

P2093

Gary R Lichtenstein

http://www.w3.org/2001/XMLSchema#string

Karen Barrett

http://www.w3.org/2001/XMLSchema#string

Kirstin Lees

http://www.w3.org/2001/XMLSchema#string

Michael A Kamm

http://www.w3.org/2001/XMLSchema#string

Raymond Joseph

http://www.w3.org/2001/XMLSchema#string

Stefan Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

Side effects of corticosteroid therapy.

Guidelines for the management of inflammatory bowel disease in adults.

Systematic review: adherence issues in the treatment of ulcerative colitis.

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.20580

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

William Jeffery Sandborn

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23141524

http://www.w3.org/2001/XMLSchema#string

P698

18671232

http://www.w3.org/2001/XMLSchema#string